In addition to increasing serum Mg2+ levels, in separate studies, the use of SGLT2 inhibitors reduced mTORC1 activation in the kidney and cardiac myocytes, further strengthening the potential benefit of this drug for patients with ADKH-RRAGD.42, 43, 44 Although it was not investigated if mTORC1 activation is dampened in patients upon dapagliflozin administration, this opens up a novel treatment option for patients with ADKH-RRAGD with hypomagnesemia, DCM, and mTORC1 overactivation. Here, SLC5A2 is linked to familial primary hypomagnesemia.